Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 3
1992 3
1993 1
1994 1
1995 3
1996 1
1998 3
1999 4
2000 7
2001 7
2002 7
2003 9
2004 5
2005 7
2006 9
2007 14
2008 10
2009 4
2010 5
2011 11
2012 9
2013 15
2014 12
2015 9
2016 8
2017 14
2018 10
2019 7
2020 8
2021 15
2022 17
2023 9
2024 14
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones.
Collora JA, Liu R, Pinto-Santini D, Ravindra N, Ganoza C, Lama JR, Alfaro R, Chiarella J, Spudich S, Mounzer K, Tebas P, Montaner LJ, van Dijk D, Duerr A, Ho YC. Collora JA, et al. Among authors: tebas p. Immunity. 2022 Jun 14;55(6):1013-1031.e7. doi: 10.1016/j.immuni.2022.03.004. Epub 2022 Mar 22. Immunity. 2022. PMID: 35320704 Free PMC article.
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J. Gulick RM, et al. Among authors: tebas p. Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1. Ann Intern Med. 2024. PMID: 39348691 Free article.
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH. Tebas P, et al. N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662. N Engl J Med. 2014. PMID: 24597865 Free PMC article. Clinical Trial.
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.
McMyn NF, Varriale J, Fray EJ, Zitzmann C, MacLeod H, Lai J, Singhal A, Moskovljevic M, Garcia MA, Lopez BM, Hariharan V, Rhodehouse K, Lynn K, Tebas P, Mounzer K, Montaner LJ, Benko E, Kovacs C, Hoh R, Simonetti FR, Laird GM, Deeks SG, Ribeiro RM, Perelson AS, Siliciano RF, Siliciano JM. McMyn NF, et al. Among authors: tebas p. J Clin Invest. 2023 Sep 1;133(17):e171554. doi: 10.1172/JCI171554. J Clin Invest. 2023. PMID: 37463049 Free PMC article.
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL. Tebas P, et al. J Clin Invest. 2024 May 1;134(9):e181576. doi: 10.1172/JCI181576. J Clin Invest. 2024. PMID: 38690741 Free PMC article. No abstract available.
Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4+ T cell reservoir.
Wu VH, Nordin JML, Nguyen S, Joy J, Mampe F, Del Rio Estrada PM, Torres-Ruiz F, González-Navarro M, Luna-Villalobos YA, Ávila-Ríos S, Reyes-Terán G, Tebas P, Montaner LJ, Bar KJ, Vella LA, Betts MR. Wu VH, et al. Among authors: tebas p. Nat Immunol. 2023 Feb;24(2):359-370. doi: 10.1038/s41590-022-01371-3. Epub 2022 Dec 19. Nat Immunol. 2023. PMID: 36536105 Free PMC article.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Among authors: tebas p. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Jadlowsky JK, et al. Among authors: tebas p. Nat Med. 2025 Apr;31(4):1134-1144. doi: 10.1038/s41591-024-03478-6. Epub 2025 Jan 20. Nat Med. 2025. PMID: 39833408
Nelfinavir mesylate.
Tebas P, Powderly WG. Tebas P, et al. Expert Opin Pharmacother. 2000 Dec;1(7):1429-40. doi: 10.1517/14656566.1.7.1429. Expert Opin Pharmacother. 2000. PMID: 11249476 Review.
252 results